COVID-19 Vaccine Solution
VAXMED’s Vaccine solution to COVID-19
VAXMED’s COVID-19 vaccines will be a broad-spectrum Coronavirus vaccine, meaning it will protect against the current SARS-CoV-2, the past original SARS-CoV, the MERS-CoV and should have cross protective attributes against the other human Coronaviruses that cause common colds that have originated from bats and likely protect against any other bat Coronaviruses which have not yet crossed to humans.
Rapid design, development and production and testing of a human Coronavirus vaccine, single shot vaccination delivering broad spectrum protection against infection by SARS-CoV-2, previous SARS, MERS and other future Coronaviruses
This is very different to other SARS-CoV-2 vaccines under development and the VAXMED vaccine is aligned well with a longer-term, overarching vaccine strategy to protect in the current and potential future outbreaks.
Even though other vaccines are ahead in development, many are potentially of limited efficacy as they only consist of the ‘Spike Protein’ as the vaccine antigen. VAXMED will be using additional structural proteins that are conserved amongst Coronavirus. It will cover the current circulating viruses and those that may still be emerging from bats.
Our vaccines will result in a better quality of protection by inducing a broad cross protective immunity to Coronaviruses in general.
Key Characteristics of VAXMED’s Coronavirus Vaccine
Even at small scale, large numbers of vaccines can be produced
Provides long-lasting protection
Will be given as a single shot vaccination
Production can be scaled, laboratory scale can supply vaccine for Australia and New Zealand. Because of the unique VAXMED production system, vaccines can be manufactured within weeks in a standard clean room with the appropriate certification
From vaccine concept design to proof of concept animal data in under 10 months, commencement of GMP manufacture in under 12 months